Raptor Pharmaceutical Reports Third Quarter 2014 Financial Results and Provides Corporate Update
06 nov. 2014 16h05 HE
|
Raptor Pharmaceutical Inc
Global Net Product Sales for PROCYSBI® of $23.8 Million for Third Quarter 2014
PROCYSBI Revenue of $52.2 Million Reached Through September
2014 PROCYSBI Revenue Guidance of $65-$70 Million...
Raptor Pharmaceutical to Hold Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, November 6, at 4:30 p.m. ET
29 oct. 2014 16h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2014 financial results on Thursday, November 6,...
Raptor Pharmaceutical Announces Management Changes
23 oct. 2014 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has strengthened its leadership team with the hiring of two new executives: David...
Raptor Pharmaceutical to Present at Leerink Rare Disease Roundtable
23 sept. 2014 08h00 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Leerink Rare Disease Roundtable in New York on...
Raptor Pharmaceutical to Present at Upcoming Investor Conference in September
27 août 2014 08h00 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Morgan Stanley Global Healthcare Conference in...
Raptor Pharmaceutical Reports Second Quarter 2014 Financial Results and Provides Corporate Update
07 août 2014 16h05 HE
|
Raptor Pharmaceutical Inc
Global net product sales for PROCYSBI® of $16.3 million reported for second quarter 2014
Raising net sales guidance for PROCYSBI to $65 to $70 million for 2014
Company to host...
Raptor Receives Orphan Drug Designation for Cysteamine Bitartrate in Huntington's Disease From the European Commission
04 août 2014 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 4, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the European Commission (EC) approved its application for orphan drug designation of...
Raptor Pharmaceutical to Hold Second Quarter 2014 Financial Results Webcast and Conference Call
28 juil. 2014 16h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 28, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release second quarter 2014 financial results after market close on Thursday,...
Raptor Pharmaceutical Enters Into $70 Million Financing Transaction and Amended Loan Agreement With HealthCare Royalty Partners
01 juil. 2014 17h13 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 1, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has entered into agreements for $70 million in funding from HealthCare Royalty...
Raptor Pharmaceutical to Participate in Three Upcoming Investor Conferences in June
10 juin 2014 08h00 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 10, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will participate in three upcoming investor conferences in...